Sales Agreements in the Pharmaceuticals Industry
223 Contracts & Agreements
- Acer Therapeutics Inc. (3 contracts)
- Aclaris Therapeutics, Inc. (2)
- Adamis Pharmaceuticals Corp (1)
- AERIE PHARMACEUTICALS INC (1)
- Aerpio Pharmaceuticals, Inc. (1)
- AGILE THERAPEUTICS INC (1)
- Akorn (2)
- ALIMERA SCIENCES INC (1)
- Ampio Pharmaceuticals, Inc. (1)
- Anthera Pharmaceuticals Inc (2)
- ARTELO BIOSCIENCES, INC. (1)
- Assertio Holdings, Inc. (1)
- Athira Pharma, Inc. (1)
- AVANIR PHARMACEUTICALS, INC. (2)
- Axsome Therapeutics, Inc. (4)
- AYTU BIOSCIENCE, INC (1)
- Baudax Bio, Inc. (2)
- BioPharmX Corp (1)
- CASSAVA SCIENCES INC (2)
- Cerecor Inc. (2)
- CHIASMA, INC (1)
- CHINA PEDIATRIC PHARMACEUTICALS, INC. (5)
- CHINA PHARMA HOLDINGS, INC. (1)
- Clearside Biomedical, Inc. (2)
- CNS Pharmaceuticals, Inc. (1)
- COGNITION THERAPEUTICS INC (1)
- ContraVir Pharmaceuticals, Inc. (2)
- CorMedix Inc. (3)
- CUMBERLAND PHARMACEUTICALS INC (6)
- Dova Pharmaceuticals Inc. (1)
- Edgewise Therapeutics, Inc. (1)
- Eloxx Pharmaceuticals, Inc. (2)
- Eton Pharmaceuticals, Inc. (3)
- Evolus, Inc. (1)
- EYENOVIA, INC. (1)
- EyePoint Pharmaceuticals, Inc. (2)
- Foamix Pharmaceuticals Ltd. (1)
- Gala Pharmaceutical Inc. (1)
- Horizon Pharma plc (1)
- INNOVATE BIOPHARMACEUTICALS, INC. (2)
- Lyra Therapeutics, Inc. (1)
- Menlo Therapeutics Inc. (1)
- MJ Holdings, Inc. (4)
- MyoKardia Inc (1)
- Nabriva Therapeutics plc (5)
- NGM BIOPHARMACEUTICALS INC (5)
- Novan, Inc. (1)
- NOVEN PHARMACEUTICALS INC (1)
- OCULAR THERAPEUTIX, INC (1)
- OMEROS CORP (5)
- OncoMed Pharmaceuticals Inc (1)
- Onconova Therapeutics, Inc. (2)
- ORAMED PHARMACEUTICALS INC. (1)
- Osmotica Pharmaceuticals plc (1)
- OTONOMY, INC. (2)
- Pacira Pharmaceuticals, Inc. (2)
- Paratek Pharmaceuticals, Inc. (2)
- ProPhase Labs, Inc. (2)
- Provention Bio, Inc. (1)
- QUANTA INC (1)
- QUESTCOR PHARMACEUTICALS INC (8)
- Ra Pharmaceuticals, Inc. (1)
- Rani Therapeutics Holdings, Inc. (1)
- REATA PHARMACEUTICALS INC (1)
- Recro Pharma, Inc. (1)
- resTORbio, Inc. (1)
- Revance Therapeutics, Inc. (1)
- Satsuma Pharmaceuticals, Inc. (1)
- SAVIENT PHARMACEUTICALS INC (1)
- SCICLONE PHARMACEUTICALS INC (1)
- SCYNEXIS INC (2)
- SenesTech, Inc. (1)
- Sonoma Pharmaceuticals, Inc. (4)
- SYNERGY PHARMACEUTICALS, INC. (1)
- Targeted Medical Pharma, Inc. (1)
- TAURIGA SCIENCES, INC. (1)
- Terns Pharmaceuticals, Inc. (1)
- Terra Tech Corp. (1)
- TETRALOGIC PHARMACEUTICALS CORP (1)
- TETRAPHASE PHARMACEUTICALS INC (1)
- TherapeuticsMD, Inc. (3)
- TIBET PHARMACEUTICALS, INC. (2)
- Tilray, Inc. (2)
- TITAN PHARMACEUTICALS INC (1)
- Trevi Therapeutics, Inc. (1)
- Trubion Pharmaceuticals, Inc (71)
- Zynerba Pharmaceuticals, Inc. (2)
- Controlled Equity OfferingSM Sales Agreement, dated September 1, 2023, between Lyra Therapeutics, Inc. and Cantor Fitzgerald & Co (Lyra Therapeutics, Inc., Filed With SEC on September 1, 2023)
- Amendment No. 1 to the Sales Agreement, dated as of August (Cerecor Inc., Filed With SEC on August 7, 2023)
- Sales Agreement (Adamis Pharmaceuticals Corp, Filed With SEC on July 24, 2023)
- Controlled Equity Offering Sales Agreement dated July 21, 2023 by and between Hepion Pharmaceuticals, Inc., and Cantor Fitzgerald & Co (ContraVir Pharmaceuticals, Inc., Filed With SEC on July 21, 2023)
- Sales Agreement, dated June 16, 2023, by and between Edgewise Therapeutics, Inc. and BofA Securities, Inc (Edgewise Therapeutics, Inc., Filed With SEC on June 16, 2023)
- Sales Agreement, dated as of May 24, 2023, by and between Eloxx Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Eloxx Pharmaceuticals, Inc., Filed With SEC on May 24, 2023)
- Sales Agreement, dated May 15, 2023, by and between Terns Pharmaceuticals, Inc. and Cowen and Company, LLC (Terns Pharmaceuticals, Inc., Filed With SEC on May 15, 2023)
- Controlled Equity OfferingSM Sales Agreement, dated as of May 12, 2023, by and between the Company and Cantor Fitzgerald & Co (Clearside Biomedical, Inc., Filed With SEC on May 12, 2023)
- Sales Agreement, dated as of May (Cerecor Inc., Filed With SEC on May 4, 2023)
- Capital On Demand Sales Agreement, dated as of May 1, 2023, between Cassava Sciences, Inc. and JonesTrading Institutional Services LLC (CASSAVA SCIENCES INC, Filed With SEC on May 1, 2023)
- Sales Agreement, dated February 23, 2023, by and among Aclaris Therapeutics, Inc., SVB Securities LLC and Cantor Fitzgerald & Co (Aclaris Therapeutics, Inc., Filed With SEC on February 23, 2023)
- Controlled Equity Offering Sales AgreementSM, dated January 6, 2023, among the Company, Cantor Fitzgerald & Co. and BTIG, LLC (Athira Pharma, Inc., Filed With SEC on January 6, 2023)
- Controlled Equity OfferingSM Sales Agreement, dated as of December 23, 2022, by and among Cognition Therapeutics, Inc., Cantor Fitzgerald & Co. and B. Riley Securities, Inc (COGNITION THERAPEUTICS INC, Filed With SEC on December 23, 2022)
- At-The-Market Sales Agreement by and between the Registrant and Virtu Americas LLC, dated November 3, 2022 (Satsuma Pharmaceuticals, Inc., Filed With SEC on November 3, 2022)
- Controlled EquitySM Sales Agreement, dated August 24, 2022, by and among Rani Therapeutics Holdings, Inc., and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (Rani Therapeutics Holdings, Inc., Filed With SEC on August 25, 2022)
- Third Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Nabriva Therapeutics plc, Filed With SEC on August 3, 2022)
- Amendment No. 1 to the Sales Agreement, dated May 13, 2022, by and between the Registrant and SVB Securities LLC (Trevi Therapeutics, Inc., Filed With SEC on May 16, 2022)
- Master Manufacturing and Supply Agreement, dated August 16, 2018, by and between DPT Laboratories, Ltd. and EPI Health, LLC (as successor-in-interest to Allergan Sales, LLC) (Novan, Inc., Filed With SEC on May 16, 2022)
- Sales Agreement - 6220 E. Dyer Santa Ana (Terra Tech Corp., Filed With SEC on April 15, 2022)
- Sales Agreement dated as of March 17, 2022, by and between the Company and Cowen and Company, LLC (Aerpio Pharmaceuticals, Inc., Filed With SEC on March 17, 2022)
- Sales Agreement, dated as of December 17, 2021, by and between the Company and Roth Capital Partners, LLC (Assertio Holdings, Inc., Filed With SEC on March 10, 2022)
- Sales Agreement, dated as of March 3, 2022, by and between Tilray Brands, Inc. and Jefferies LLC and Canaccord Genuity LLC (Tilray, Inc., Filed With SEC on March 3, 2022)
- Sales Agreement dated March 1, 2022, by and between Axsome Therapeutics, Inc. and SVB Securities LLC (Axsome Therapeutics, Inc., Filed With SEC on March 1, 2022)
- Controlled Equity OfferingSM Sales Agreement dated January 10, 2022 by and among Agile Therapeutics, Inc. and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (AGILE THERAPEUTICS INC, Filed With SEC on January 10, 2022)
- Sales Agreement dated December 28, 2021 between the Registrant and ThinkEquity LLC (ProPhase Labs, Inc., Filed With SEC on December 29, 2021)
- Amendment No. 1 to the At Market Issuance Sales Agreement, dated December 27, 2021, by and between Cumberland Pharmaceuticals Inc. and B. Riley Securities, Inc. (formerly B. Riley... (CUMBERLAND PHARMACEUTICALS INC, Filed With SEC on December 27, 2021)
- Sales Agreement, dated as of September 30, 2021, by and between Eloxx Pharmaceuticals, Inc. and SVB Leerink, LLC (Eloxx Pharmaceuticals, Inc., Filed With SEC on September 30, 2021)
- Sales Agreement, dated as of September 8, 2021, by and between Osmotica Pharmaceuticals plc and Cantor Fitzgerald & Co (Osmotica Pharmaceuticals plc, Filed With SEC on September 8, 2021)
- Cultivation and Sales Agreement between MJ Holdings, Inc. and Green Grow Investments Corporation dated May 7, 2021 (MJ Holdings, Inc., Filed With SEC on August 25, 2021)
- Cultivation and Sales Agreement between MJ Holdings, Inc. and RK Grow LLC dated June 22, 2021 (MJ Holdings, Inc., Filed With SEC on August 25, 2021)
- Sales Agreement dated August 12, 2021 (CorMedix Inc., Filed With SEC on August 12, 2021)
- Controlled Equity Offering Sales AgreementSM, dated August 12, 2021, by and between VYNE Therapeutics Inc. and Cantor Fitzgerald & Co (Menlo Therapeutics Inc., Filed With SEC on August 12, 2021)
- Second Amendment to Sales Promotion and Distribution Agreement, dated as of April 12, 2021, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD... (Nabriva Therapeutics plc, Filed With SEC on August 5, 2021)
- First Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Nabriva Therapeutics plc, Filed With SEC on August 5, 2021)
- Sales Agreement, dated as of August 4, 2021, between Otonomy, Inc. and Cowen and Company, LLC (OTONOMY, INC., Filed With SEC on August 4, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated June 4, 2021, by and between Aytu BioPharma, Inc. and Cantor Fitzgerald & Co (AYTU BIOSCIENCE, INC, Filed With SEC on June 7, 2021)
- Sales Agreement, dated May 20, 2021, by and among Aclaris Therapeutics, Inc., SVB Leerink LLC and Cantor Fitzgerald & Co (Aclaris Therapeutics, Inc., Filed With SEC on May 20, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated May 17, 2021, between SCYNEXIS, Inc. and Ladenburg Thalmann & Co. Inc (SCYNEXIS INC, Filed With SEC on May 18, 2021)
- Controlled Equity OfferingSM Sales Agreement, dated May 17, 2021, between SCYNEXIS, Inc. and Cantor Fitzgerald & Co (SCYNEXIS INC, Filed With SEC on May 18, 2021)
- At-the-Market Sales Agreement, dated May 17, 2021, by and between Paratek Pharmaceuticals, Inc. and BTIG, LLC (Paratek Pharmaceuticals, Inc., Filed With SEC on May 17, 2021)